Last reviewed 2026-04-20 · How we verify

Erbocain (FOMOCAINE)

Phase 2 active Small molecule

Erbocain (generic name: FOMOCAINE) is a fomocaine drug. It is currently in Phase 2 development.

Erbocain works by blocking the action of certain chemicals in the body to produce its therapeutic effect.

Erbocain, also known as FOMOCAINE, is a small molecule fomocaine drug. Its exact target is unknown, but it is used to treat certain conditions. The commercial status of Erbocain is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacology and clinical use.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FOMOCAINE
Drug class	fomocaine
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your body's chemistry as a complex conversation. Erbocain is like a 'mute button' that helps reduce the noise and calm things down, allowing the body to function more normally. This can help alleviate symptoms of certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Erbocain CI brief — competitive landscape report
Erbocain updates RSS · CI watch RSS

Frequently asked questions about Erbocain

What is Erbocain?

Erbocain (FOMOCAINE) is a fomocaine drug.

How does Erbocain work?

Erbocain works by blocking the action of certain chemicals in the body to produce its therapeutic effect.

What is the generic name of Erbocain?

FOMOCAINE is the generic (nonproprietary) name of Erbocain.

What drug class is Erbocain in?

Erbocain belongs to the fomocaine class. See all fomocaine drugs at /class/fomocaine.

What development phase is Erbocain in?

Erbocain is in Phase 2.

Drug class: All fomocaine drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing